Microbiome Space in Spotlight as Microbiotica Sets Funding Record
Competition is heating up in the microbiome niche as UK-based Microbiotica raised €60M (£50M) in…
The potential of the microbiome to be used for the development of promising therapeutics and diagnostic approaches has spurred a hype around this emerging field. Over the last decade, researchers have found correlations between the human microbiome and a number of diseases, including inflammatory bowel disease, diabetes, autoimmune diseases, cancer, depression, and many more. As the number of clinical trials grows, investor interest is increasing.
Read on to find out more about the flourishing microbiome field and how it shows promise for the treatment of a large variety of diseases.
Beyond the Gut: An Atlas of the Human Microbiome
This report discusses the role of the gut and blood microbiomes in different diseases and how they can be used for biomarker discovery and for the development of therapeutics.
Go to ReportCompetition is heating up in the microbiome niche as UK-based Microbiotica raised €60M (£50M) in…
As increasing attention turns to microbiome-based therapeutics, the Scottish biotech Enterobiotix has closed a Series…
The microbiome could pave new cancer immunotherapy inroads for European biotechs, bolstered by preclinical findings…
Scotland has a thriving life sciences ecosystem with strengths in oncology, genetic engineering, and industrial…
With a €49M ($60M) Series A, the French firm eureKARE debuted this month with the…
This week, the Paris-based Eligo Bioscience became one of a growing number of biotechs to…
Providers of microbiome therapies worldwide have been hit by pandemic restrictions on the harvest of…
French microbiome biotech Enterome has raised €46.3M in Series E funding to progress its cancer…
The microbiome company LNC Therapeutics has entered into a licensing agreement to use a specific…
For Isabelle de Cremoux, CEO and Managing Partner at Seventure Partners, 2020 was going to…
Ingestible pellets containing a charcoal-like treatment -- designed by the French company Da Volterra --…
French company MaaT Pharma has raised €18M in Series B financing that will support phase…